November 17, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise on the use of carvedilol tablets in diabetic patients; the risk for potentially fatal ...
A combination of silybin and carvedilol is more effective than either drug alone for treating liver fibrosis, found a new study published in Targetome. Liver fibrosis is a chronic and multifactorial ...
The U.S. Food and Drug Administration today approved the first generic versions of Coreg (carvedilol). Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to ...
WASHINGTON -- A Food and Drug Administration panel Tuesday endorsed one of GlaxoSmithKline's requests to expand the approved use of the drug Coreg. The panel endorsed the use of Coreg in preventing ...
The Supreme Court declined to hear Teva's challenge to a $235 million award to GlaxoSmithKline in a patent dispute over generic drugs involving heart medication Coreg, according to a Reuters report.
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A building belonging to Teva Pharmaceutical Industries, the world's biggest generic drugmaker and Israel's largest ...
NEW YORK Teva has settled a case against Dr. Reddy’s concerning its patent on carvedilol, the active ingredient in GlaxoSmithKline’s heart drug Coreg. Teva started filing suits last June to protect ...
Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. In the patent "carve-out" case, GSK didn't bring enough ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results